Brachyury ASO Targeting for Chordoma

Tech ID: 32983 / UC Case 2023-046-0

Patent Status

Patent Pending

Brief Description

This invention are inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of using the inhibitory nucleic acids to treat carcinomas.

Suggested uses

Brachyury (also known as “TBXT”) has been shown to be overexpressed in carcinomas of the lung, breast, colon, prostate, and liver, as well as in chordoma. Brachyury has been associated with the epithelial-mesenchymal transition in human tumors, and is under investigation as a drug target for a wide range of carcinomas. Chordoma is a malignant sarcoma originating from notochord cells in the vertebrae and is rare (1:1,000,000), with 300 diagnoses per year in the United States. A chordoma tumor is slow growing; however, treatment is challenging due to the proximity of the tumor to the spinal cord, and the tendency for recurrence following surgery and radiation. There are no systemic targeted therapies for chordoma, and consequently, patients with advanced and metastatic disease face poor prognoses.  This invention are inhibitory nucleic acids to treat carcinomas.

Advantages

There are no systemic targeted therapies for chordoma, and consequently, patients with advanced and metastatic disease face poor prognoses.

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Naar, Anders Michael

Other Information

Categorized As